Biohaven Pharmaceutical Holding Stock Today
| BHVN Stock | USD 29.87 1.17 3.77% |
PerformanceVery Weak
| Odds Of DistressLow
|
Biohaven Pharmaceutical is selling at 29.87 as of the 26th of March 2025; that is 3.77 percent decrease since the beginning of the trading day. The stock's open price was 31.04. Biohaven Pharmaceutical has less than a 15 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 26th of December 2024 and ending today, the 26th of March 2025. Click here to learn more.
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. The company has 102.06 M outstanding shares of which 8.28 M shares are currently shorted by private and institutional investors with about 10.98 trading days to cover. More on Biohaven Pharmaceutical Holding
Moving against Biohaven Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Biohaven Stock Highlights
| Chairman | Vlad Coric |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Biohaven Pharmaceutical Holding (BHVN) is traded on New York Stock Exchange in USA. It is located in 215 Church Street, New Haven, CT, United States, 06510 and employs 256 people. Biohaven Pharmaceutical is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.17 B. Biohaven Pharmaceutical conducts business under Biotechnology sector and is part of Health Care industry. The entity has 102.06 M outstanding shares of which 8.28 M shares are currently shorted by private and institutional investors with about 10.98 trading days to cover.
Biohaven Pharmaceutical Holding currently holds about 23.21 M in cash with (582.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.48.
Check Biohaven Pharmaceutical Probability Of Bankruptcy
Ownership AllocationBiohaven Pharmaceutical holds a total of 102.06 Million outstanding shares. The majority of Biohaven Pharmaceutical Holding outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biohaven Pharmaceutical to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biohaven Pharmaceutical. Please pay attention to any change in the institutional holdings of Biohaven Pharmaceutical Holding as this could imply that something significant has changed or is about to change at the company. Also note that nearly three million four hundred twenty-nine thousand three hundred eighty-four invesors are currently shorting Biohaven Pharmaceutical expressing very little confidence in its future performance.
Check Biohaven Ownership Details
Biohaven Pharmaceutical Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Biohaven Pharmaceutical market risk premium is the additional return an investor will receive from holding Biohaven Pharmaceutical long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (0.28) | |||
| Treynor Ratio | (0.12) |
Biohaven Stock Against Markets
Biohaven Pharmaceutical Corporate Directors
| John Childs | Independent Director | Profile | |
| Robert Hugin | Independent Director | Profile | |
| Michael Heffernan | Lead Independent Director | Profile | |
| Julia Gregory | Independent Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.